Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer.

Therapeutics confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

How one man, along with his care team, turned an all-consuming cancer diagnosis into a management strategy with inspiration ...

Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patientTreatment well-tolerated and patient remains on study with ...

Bria-OTS is currently being investigated as a personalized off-the-shelf immunotherapy in a Phase 1/2a dose escalation study for metastatic recurrent breast cancer. The study will evaluate the safety ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...